HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NAD SWIFT Cases Get Swifter, More Frequent As Stakeholders Embrace Fast-Track Process

Executive Summary

The BBB National Program Inc. expects to double the number of National Advertising Division SWIFT reviews completed in 2023 compared with last year as stakeholders grow more comfortable with the process. At its annual conference in Philadelphia 19-20 September, NAD said it is speeding up the time it takes to complete both SWIFT and standard track reviews.

You may also be interested in...



NAD Says Fast-Track SWIFT Reviews Doubled Over Past Year

Greater awareness of Fast-Track SWIFT and improved understanding of cases appropriate for the process have nearly doubled the number of SWIFT cases evaluated by the National Advertising Division over the past 12 months, NAD attorney Daniel Range said at the NAD 2022 conference in Washington.

NAD Offers Complex And Fast Tracks: Not All Advertising Claim Reviews Are Alike

NAD will assign three attorneys at the beginning of each Complex Track review instead of one, director Laura Brett said in a recent interview. The industry self-regulation group also recently launched its Fast-Track program for more simple ad claim challenges that rarely have been made.

Unilever Squelches Dr. Squatch Comparative Claims In NAD Forum; Advertiser Can Keep Its 'Sh*t List’

Dr. Squatch was able to substantiate that it uses “no harmful ingredients” as well as certain claims about avoiding a “Sh*t list” of ingredients, but agreed to modify other claims the National Advertising Division deemed falsely disparage competitor products, such as Unilever’s Dove personal-care brand.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154037

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel